"Bristol's earnings recovery depends on upholding the patent on Plavix, and the odds are only 60-40 in its favor," said Deutsche Bank analyst Barbara Ryan. "If Bristol loses, it would have to cut its dividend and even sell the company."
See how mixed the latest figures are here
Insiders' view: Roll on April. At least it's after the Ides of March!
No comments:
Post a Comment